Cancer Immunotherapy: A New Target Emerges as Cells ‘Barf’ Proteins
Researchers have identified a surprising location for a key protein, Src, on the surface of cancer cells – a place it shouldn’t be. This discovery, reported in Science, could unlock new avenues for immunotherapy, particularly for solid tumors, which have historically been hard to treat with this approach.
The Unexpected Discovery of Src
Jim Wells, a biologist at the University of California San Francisco, stumbled upon this finding while studying proteins on cancer cell surfaces. Src, typically found inside cells, was unexpectedly present on the exterior of malignant cells, but not healthy tissue. This mislocalization is described as an “accident” and a “serendipitous one” by Wells, hinting at the unpredictable nature of scientific breakthroughs.
Why This Matters for Immunotherapy
Immunotherapy works by helping the immune system recognize and attack cancer cells. A major challenge is finding unique targets – proteins present on cancer cells but not healthy cells – that the immune system can latch onto. The presence of Src on the surface of cancer cells presents a potential new target. Kathleen Yates, a biologist at the Broad Institute of MIT and Harvard University, called the finding “provocative and exciting,” but cautioned that it’s still early days.
Solid Tumors: A Particularly Tough Challenge
Solid tumors, unlike blood cancers, have proven resistant to many immunotherapy approaches. Finding effective targets on these tumors has been a significant hurdle. If Src proves to be a viable target, it could represent a major step forward in treating a wide range of cancers, including breast, lung, and colon cancer.
The Next Steps: From Lab to Clinic
While the discovery is promising, significant research remains. Scientists need to determine how reliably Src appears on the surface of different cancer types and whether targeting it will actually lead to clinical benefits. Yates emphasized the importance of translational impact – whether this finding will ultimately improve patient outcomes.
Frequently Asked Questions
What is immunotherapy?
Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. It works by boosting or changing how your immune system works to recognize and attack cancer cells.
What are solid tumors?
Solid tumors are abnormal masses of tissue that can occur in any part of the body. They are different from blood cancers, such as leukemia, which do not form a solid mass.
What is Src?
Src is a protein that normally resides inside cells. Its presence on the surface of cancer cells, where it shouldn’t be, is a surprising discovery that may offer a new target for immunotherapy.
Stay informed about the latest cancer research. Subscribe to STAT+ for exclusive in-depth reporting.
Related reading
- Urgent Call for Chronic Pain Model of Care
- Cholesterol Supplement Lowers Lipids in Healthy Adults: RCT
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)